Skip to main content

REGENXBIO Inc.

RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001590877

In the last 90 days, REGENXBIO Inc. insiders filed 1 open-market purchase and 2 sales; 165 institutions reported holding it in 13F filings for Q2 2026, worth $507.0M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by REGENXBIO Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $949.4K in total
Open-market sells
2 filings
1 insider, $718.2K in total
Insiders trading
2
Net value
+$231.1K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for REGENXBIO Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for REGENXBIO Inc.
NameTitleLast reported holdingLast filingFilings, past year
Malzahn CraigChief Technology Officer81,960Sep 3, 20263
Chan MitchellChief Financial Officer122,815Sep 3, 20262
Ciongoli Gregory AustinDirector118,035Aug 27, 20261
Pakola SteveChief Medical Officer205,541Aug 4, 20268
Christmas Patrick J.Chief Strategy & Legal Officer205,968Aug 4, 20264
Simpson CurranChief Executive Officer338,053Jul 6, 20265
Migausky George VDirector28,861Jun 2, 20261
Karabelas Argeris NDirector28,861Jun 2, 20261
Stump David CDirector28,861Jun 2, 20261
Tasse DanielDirector28,861Jun 2, 20261
Mills Kenneth T.Director495,925Jun 2, 20262
Fox Allan M.Director28,861Jun 2, 20261
Glucksmann AlexandraDirector28,861Jun 2, 20261
Zachary JenniferDirector31,871Jun 2, 20261
Bennett JeanDirector28,861Jun 2, 20261
Danos OlivierChief Scientific Officer226,348Apr 4, 20250
Vasista VittalChief Financial Officer246,534Mar 21, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 27, 2026 (view filing)7:03 PM ETAug 26-271 dayCiongoli Gregory AustinDirectorPPurchase+102.6K$9.25+$949.4K+664.9%118.0K after2 lots
Jul 6, 2026 (view filing)4:51 PM ETJul 24 daysPakola SteveChief Medical OfficerSSale−2.16K$13.64−$29.5K−1.0%213.0K after10b5-1
Jul 1, 2026 (view filing)8:08 PM ETJun 29-Jul 12 daysPakola SteveChief Medical OfficerSSale−56.3K$12.23−$688.8K−20.9%213.0K after2 lots
May 13, 2026 (view filing)May 112 daysPakola SteveChief Medical OfficerSSale−15.3K$11.02−$168.7K−6.2%232.6K after10b5-1
Mar 12, 2026 (view filing)Mar 102 daysPakola SteveChief Medical OfficerSSale−5.12K$10.35−$53.0K−2.0%247.9K after10b5-1
Oct 10, 2025 (view filing)Oct 91 daySimpson CurranChief Executive OfficerSSale−20.8K$12.62−$262.6K−8.8%216.2K after10b5-1
Oct 1, 2025 (view filing)Sep 292 daysSimpson CurranChief Executive OfficerSSale−7.62K$10.03−$76.5K−3.1%237.0K after10b5-1
Sep 12, 2025 (view filing)Sep 102 daysSimpson CurranChief Executive OfficerSSale−7.73K$10.02−$77.5K−3.1%244.6K after10b5-1
May 14, 2025 (view filing)May 122 daysMills Kenneth T.DirectorSSale−20.6K$7.91−$163.0K−4.2%475.1K after10b5-1
Oct 2, 2024 (view filing)Oct 11 dayKarabelas Argeris NDirectorSSale−10.0K$10.11−$101.1K−47.0%11.3K after10b5-1
Sep 4, 2024 (view filing)Sep 31 dayKarabelas Argeris NDirectorSSale−10.0K$11.56−$115.6K−47.0%11.3K after2 lots10b5-1
Aug 5, 2024 (view filing)Aug 14 daysKarabelas Argeris NDirectorSSale−10.1K$13.51−$136.5K−47.2%11.3K after3 lots10b5-1
Aug 5, 2024 (view filing)Aug 14 daysSimpson CurranChief Executive OfficerSSale−100$15.00−$1.50K−0.1%170.0K after10b5-1
Jul 30, 2024 (view filing)Jul 291 dayKarabelas Argeris NDirectorSSale−11.0K$15.05−$165.6K−49.4%11.3K after10b5-1
Jul 30, 2024 (view filing)Jul 291 daySimpson CurranChief Executive OfficerSSale−9.65K$15.04−$145.1K−5.4%170.1K after10b5-1
Jul 26, 2024 (view filing)Jul 24-252 daysMills Kenneth T.DirectorSSale−27.6K$13.88−$383.0K−6.3%408.0K after2 lots10b5-1
Jul 18, 2024 (view filing)Jul 16-172 daysMills Kenneth T.DirectorSSale−2.41K$13.77−$33.2K−0.6%408.0K after2 lots10b5-1
Jul 3, 2024 (view filing)Jul 12 daysKarabelas Argeris NDirectorSSale−10.0K$11.27−$112.7K−47.0%11.3K after10b5-1
May 16, 2024 (view filing)May 142 daysMills Kenneth T.President and CEOSSale−15.0K$15.81−$237.2K−3.5%408.0K after10b5-1
Apr 17, 2024 (view filing)Apr 152 daysMills Kenneth T.President and CEOSSale−15.0K$18.19−$272.9K−3.5%408.0K after10b5-1
Mar 18, 2024 (view filing)Mar 144 daysMills Kenneth T.President and CEOSSale−15.0K$21.86−$327.9K−3.5%408.0K after10b5-1
Mar 7, 2024 (view filing)Mar 52 daysPakola SteveChief Medical OfficerSSale−12.9K$28.36−$365.2K−10.7%107.2K after10b5-1
Feb 16, 2024 (view filing)Feb 142 daysMills Kenneth T.President and CEOSSale−15.0K$16.75−$251.3K−3.5%408.0K after2 lots10b5-1
Jan 18, 2024 (view filing)Jan 162 daysMills Kenneth T.President and CEOSSale−45.0K$15.18−$683.1K−9.9%408.0K after10b5-1
Jan 4, 2024 (view filing)Jan 31 dayPakola SteveChief Medical OfficerSSale−17.2K$17.39−$299.8K−13.9%107.2K after10b5-1
Dec 21, 2023 (view filing)Dec 192 daysMills Kenneth T.President and CEOSSale−45.0K$19.69−$886.0K−11.2%355.3K after10b5-1
Jan 5, 2023 (view filing)Jan 32 daysPakola SteveChief Medical OfficerSSale−3.14K$22.17−$69.6K−20.5%12.2K after
Aug 31, 2022 (view filing)Aug 301 dayVasista VittalChief Financial OfficerSSale−2.40K$30.24−$72.6K−1.7%135.2K after
Aug 8, 2022 (view filing)Aug 4-54 daysVasista VittalChief Financial OfficerSSale−17.7K$35.19−$622.1K−11.4%137.6K after2 lots
Aug 3, 2022 (view filing)Aug 12 daysVasista VittalChief Financial OfficerSSale−2.40K$31.26−$75.0K−1.5%155.2K after
Jul 15, 2022 (view filing)Jul 13-142 daysVasista VittalChief Financial OfficerSSale−4.80K$30.01−$144.0K−3.0%157.6K after2 lots
Jan 4, 2022 (view filing)Jan 31 dayPakola SteveChief Medical OfficerSSale−1.60K$33.75−$53.9K−16.2%8.25K after
Dec 27, 2021 (view filing)Dec 22-235 daysFox Allan M.DirectorSSale−112.9K$34.69−$3.92M−6.9%1.53M after3 lots
Nov 10, 2021 (view filing)Nov 82 daysMills Kenneth T.President and CEOSSale−1.50K$40.00−$60.0K−0.5%281.0K after
Sep 29, 2021 (view filing)Sep 272 daysMills Kenneth T.President and CEOSSale−1.50K$42.19−$63.3K−0.5%281.0K after
Sep 21, 2021 (view filing)Sep 174 daysFox Allan M.DirectorSSale−48.2K$45.04−$2.17M−3.4%1.36M after
Sep 15, 2021 (view filing)Sep 13-142 daysMills Kenneth T.President and CEOSSale−38.0K$44.71−$1.70M−11.9%281.0K after2 lots